Outcome of Board Meeting held today i.e., Friday, 16th May, 2025 at Registered Office of the Company has inter alia considered and approved the following businesses: 1.Audited Standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.0 pts more than Nifty Microcap 250 and 8.0 pts more than its Civil Construction peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanta Industries' board approved audited Q4 and FY25 results showing a sharp divergence between standalone and consolidated numbers. Standalone FY25 revenue fell to ₹22.85 crore from ₹37.24 crore (down ~39%) with a loss of ₹1.20 crore versus a ₹92 lakh profit last year. Consolidated revenue jumped to ₹109.80 crore from ₹37.24 crore (up ~195%), driven by newly acquired subsidiary Trinity Ganesh Pvt Ltd, but still posted a consolidated loss of ₹1.32 crore. Operating cash flow remained negative at ₹5.38 crore (consolidated). The board approved acquiring a 35% stake in Angolan pharma firm Angav Indústria Farmacêutica S.A. to expand into pharma distribution, and approved sale of ~6.25 Bigha of land at Sanand, Ahmedabad. New Internal Auditor (Rahul Doshi & Co.) and Secretarial Auditor (Jitendra Parmar & Associates, replacing Jay Pandya) were appointed. Company Secretary Vinita Keswani resigned effective 6 May 2025.
Mixed signals for shareholders: consolidated revenue growth from the new subsidiary is positive, but both standalone and consolidated PAT turned negative with continuing negative operating cash flow. The Angola entry adds international pharma exposure but execution risk is high, and the land sale may provide some liquidity. Watch for further clarity on subsidiary performance and capital raising.